Immune checkpoint inhibitors (ICI) redefined the treatment of advanced melanoma in 2011 with the approval of ipilimumab, a CTLA-4 inhibitor, following the results of MDX010–20 showing significant improvement in survival with acceptable toxicity (17, 18). Here, CTLA4 is linked to melanoma.